Table 1 Characteristics of patients (n = 103)
Characteristics | No. of patients (%) | p value | |||
|---|---|---|---|---|---|
All patients | Group A (n = 34) | Goup B (n = 34) | Group C (n = 35) | ||
Sex | 0.818 | ||||
Male | 88 (85.4) | 30 (88.2) | 29 (85.3) | 29 (82.9) | |
Female | 15 (14.6) | 4 (11.8) | 5 (14.7) | 6 (17.1) | |
Age (year) | 0.084 | ||||
Median | 58 | 61 | 58 | 53 | |
Range | 30 ~ 79 | 38 ~ 79 | 34 ~ 77 | 30 ~ 72 | |
ECOG PS | 0.569 | ||||
0–1 | 87 (84.5) | 27 (79.4) | 29 (85.3) | 31 (88.6) | |
2 | 16 (15.5) | 7 (20.6) | 5 (14.7) | 4 (11.4) | |
Histology | 0.315 | ||||
Squamous cell carcinoma | 54 (52.4) | 22 (64.7) | 18 (52.9) | 14 (40.0) | |
Adenocarcinoma | 45 (43.7) | 10 (29.4) | 15 (44.1) | 20 (57.1) | |
Adeno-squamous cell carcinoma | 2 (1.9) | 1 (2.9) | 0 (0) | 1 (2.9) | |
Lymphoepithelioma like carcinoma | 2 (1.9) | 1 (2.9) | 1 (2.9) | 0 (0) | |
Clinical stage (7th edition) | 0.229 | ||||
IIIA | 39 (37.9) | 9 (26.5) | 14 (41.2) | 16 (45.7) | |
IIIB | 64 (62.1) | 25 (73.5) | 20 (58.8) | 19 (54.3) | |
Actual radiation dose (Gy) | 0.259 | ||||
Median | 63.8 | 63.5 | 63.9 | 64.0 | |
Range | 55.6 ~ 69.3 | 57.2 ~ 65.9 | 59.5 ~ 69.3 | 55.6 ~ 68.2 | |
Radiation fraction size (Gy) | < 0.001 | ||||
Median | 2.4 | 2.1 | 2.4 | 2.8 | |
Range | 2.0 ~ 3.1 | 2.0 ~ 2.2 | 2.2 ~ 2.5 | 2.5 ~ 3.1 | |
Overall treatment time (weeks) | < 0.001 | ||||
Median | 5.3 | 6.0 | 5.3 | 4.6 | |
Range | 3.7 ~ 7.9 | 5.4 ~ 7.9 | 4.7 ~ 7.5 | 3.7 ~ 6.0 | |
Concurrent chemotherapy | 0.170 | ||||
cisplatin + Paclitaxel/Docetaxel | 73 (70.9) | 20 (58.8) | 25 (73.5) | 28 (80.0) | |
cisplatin + Pemetrexed | 14 (13.6) | 4 (11.8) | 6 (17.6) | 4 (11.4) | |
cisplatin + Etoposide | 2 (1.9) | 1 (2.9) | 1 (2.9) | 0 | |
Others | 14 (13.6) | 9 (26.5) | 2 (5.9) | 3 (8.6) | |